Although BCL-2 inhibitors represent the first generation of senolytics, their clinical application is limited by their on-target and dose-limiting toxicity associated with hematological issues, such as neutropenia and thrombocytopenia [16]. Here, BCL2 is linked to Thrombocytopenia.